Blauvelt A, Sofen H, Lambert J, Merola JF, Lebwohl M, Hoyt K, Banerjee S, Scharnitz T, Crowley JJ. Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data . J of Skin [Internet]. 2024Jul.23 [cited 2024Jul.23];8(4):s405. Available from: https://jofskin.org/index.php/skin/article/view/2855